Sugi Predict

Sugi Predict / Compounds / SCHEMBL894775

SCHEMBL894775

SCHEMBL894775

CC(=O)N[C@](CCCCB1OC(C)(C)C(C)(C)O1)(C(=O)O)[C@H]1CCN(c2ccc(Cl)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.38
▸ ACACB O00763 1/20 0.35
▸ DRD4 P21917 5/20 0.33
▸ DRD2 P14416 4/20 0.33
▸ WDR91 A4D1P6 3/20 0.33
▸ MCHR1 Q99705 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ARG1 P05089 2/20 0.32
▸ ARG2 P78540 2/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ HTR1A P08908 1/20 0.31
▸ HTR2A P28223 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10207361 0.91 DRD4 (0.34) NOTUMACACBDRD4DRD2WDR91
SCHEMBL894372 0.78 NOTUM (0.43) NOTUMACACBDRD4DRD2WDR91
SCHEMBL2583727 0.78 NOTUM (0.43) NOTUMACACBDRD4DRD2WDR91
SCHEMBL894373 0.78 NOTUM (0.43) NOTUMACACBDRD4DRD2WDR91
SCHEMBL895492 0.78 NOTUM (0.43) NOTUMACACBDRD4DRD2WDR91
SCHEMBL895493 0.78 NOTUM (0.43) NOTUMACACBDRD4DRD2WDR91
SCHEMBL10207449 0.76 DEGS1 (0.37) DRD4DRD2MAPTHTR1AHTR2A
SCHEMBL895101 0.73 CCR1 (0.31) MCHR1
SCHEMBL23853717 0.72 CXCR3 (0.33) DRD4DRD2
SCHEMBL894543 0.72 PTGES (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2018-09-06 — — US disclosed
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 — — US disclosed
US-9040703-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2015-05-26 — — US disclosed
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-12-18 — — US disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 NOTUM 2722/4885ACACB 3551/4885DRD4 407/4885
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 NOTUM 2722/4885ACACB 3551/4885DRD4 407/4885
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 NOTUM 2722/4885ACACB 3551/4885DRD4 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.